Powerful Beauty-Enhancing Nutrient Blend Our beauty and glow IV contains precisely balanced therapeutic nutrients designed for comprehensive skin enhancement and detoxification: Master Antioxidant Complex: Glutathione for cellular detoxification and skin brightening High-dose vitamin C for collagen synthesis and radiance Alpha-lipoic acid for antioxidant protection and skin health Selenium for antioxidant enzyme support and skin protection Skin Radiance Enhancers: Biotin for healthy skin, hair, and nail growth Zinc for skin healing and cellular regeneration B-complex vitamins for cellular energy and skin metabolism Amino acids for collagen production and skin repair Beauty & Glow Infusion Benefits at Avabello Aesthetics Professional beauty and glow IV therapy provides multifaceted aesthetic enhancement through targeted nutritional support: Enhanced Skin Radiance: Improved skin brightness and luminous glow Reduced dullness and enhanced complexion clarity Increased skin luminosity and natural radiance Enhanced skin texture and smoothness Powerful Detoxification: Cellular detoxification and toxin elimination Improved liver function and metabolic cleansing Enhanced lymphatic drainage and waste removal Reduced oxidative stress and cellular damage Anti-Aging Benefits: Stimulated collagen production for firmer skin Reduced fine lines and wrinkles Improved skin elasticity and firmness Enhanced cellular regeneration and repair Overall Beauty Enhancement: Healthier hair growth and strength Stronger nail growth and appearance Improved energy levels and vitality Enhanced overall wellness and beauty from within Optimal Candidates for Beauty & Glow Therapy Beauty and glow IV therapy benefits individuals seeking enhanced skin radiance, anti-aging support, and comprehensive detoxification
Disclosures: Muhammad Atif Zahoor: Nothing to Disclose, Nahla Fadlelmawla: Nothing to Disclose, Adrian Kuipery: Nothing to Disclose, Joshua Feld: Nothing to Disclose, Alexander Mosa: Nothing to Disclose, Adam Gehring: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support 383 TENOFOVIR ALAFENAMIDE FUMARATE IN TREATMENT-NAVE CHRONIC HEPATITIS B PATIENTS WITH LIVER FIBROSIS: A PRELIMINARY NON-INVASIVE RESULTS OF 96 WEEKS Jialing Zhou 1 Xiaoning Wu 1 chuanwu zhu 2 Jiming Zhang 3 Ping Li 4 Tao Han 5 huiguo ding 6 Chenghai Liu 7 Wen Xie 8 Qing Xie 9 Yali Zong 10 Hong You 11 Jidong Jia 12 , 1 Beijing Friendship hospital, Capital medicine university, 2 The Fifth Peoples Hospital of Suzhou, China, 3 Huashan Hospital, Shanghai Medical College, Fudan University, China, 4 Tianjin Second Peoples Hospital, China, 5 Tianjin Medical University, Tianjin Union Medical Center, 6 Beijing Youan Hospital, Capital Medical University, China, 7 Shanghai Traditional Chinese Medicine Hospital, 8 Beijing Ditan Hospital, Capital Medical University, Beijing, China, 9 Ruijin Hospital, 10 The Ninth Hospital of Nanchang, China, 11 Capital Medical University, 12 Beijing Friendship Hospital, Capital Medical University, China Background: To investigate the antifibrotic efficacy and safety of tenofovir alafenamide (TAF) in treatment-nave chronic hepatitis B (CHB) with liver fibrosis
Autosomal dominant mutations in presenilin 1, presenilin 2 ( PSEN1 and PSEN2 ), and the amyloid precursor protein ( APP ) genes account for about 10% of the familial AD cases (FAD) and typically is associated with early-onset
Metabolism 119:154767
FEMS Yeast Res 5:12151228
